Table of Contents PART 01: Executive summary PART 02: Scope of the report • Market overview • Assumptions • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Highlights PART 05: Disease overview PART 06: Pipeline analysis PART 07: Market landscape • Market overview • Five forces analysis PART 08: Market segmentation by disease type • Global hemophilia B drugs market • Global hemophilia B inhibitors market PART 09: Market segmentation by type of therapy • Recombinant therapies • Plasma-derived therapies PART 10: Market segmentation by type of disease management • Prophylaxis • On-demand therapy • Inhibitor therapy PART 11: Geographical segmentation • Factor IX drugs market in Americas • Factor IX drugs market in EMEA • Factor IX drugs market in APAC PART 12: Market drivers • Shifting toward half-life drugs • Special designations promote novel launches • Growing pipeline with increased focus to meet unmet demand PART 13: Impact of drivers PART 14: Market challenges • Emerging price war in the industry • Low penetration rate • Lack of complete remission • High entry barriers PART 15: Impact of drivers and challenges PART 16: Market trends • Increasing focus on gene therapy • Increase in investments in the production and discovery • Strategic initiatives should lead to consolidation PART 17: Vendor landscape • Competitive scenario PART 18: Key vendor analysis • Biogen • CSL Behring • Novo Nordisk • Pfizer • Shire PART 19: Appendix • List of abbreviations List of Exhibits Exhibit 01: Product offerings Exhibit 02: Process of gene therapy Exhibit 03: Key buying criteria and customer segments of global factor IX deficiency treatment market Exhibit 04: Key customer segments of factor IX deficiency treatment market Exhibit 05: Pipeline analysis Exhibit 06: Key clinical trials Exhibit 07: Global factor IX deficiency treatment market snapshot Exhibit 08: Global factor IX deficiency treatment market by revenue 2016-2021 ($ millions) Exhibit 09: Five forces analysis Exhibit 10: Hemophilia B drugs market for global factor IX deficiency treatment market 2016-2021 ($ millions) Exhibit 11: Hemophilia B inhibitors market for global factor IX deficiency treatment market 2016-2021 ($ millions) Exhibit 12: Global factor IX recombinant therapies market 2016-2021 ($ millions) Exhibit 13: Global factor IX plasma-derived therapies market 2016-2021 ($ millions) Exhibit 14: Segmentation of factor IX drugs market by type of disease management 2016 Exhibit 15: Factor IX deficiency treatment market in Americas 2016-2021 ($ millions) Exhibit 16: Factor IX deficiency treatment market in EMEA 2016-2021 ($ millions) Exhibit 17: Factor IX deficiency treatment market in APAC 2016-2021($ millions) Exhibit 18: Launch of half-life drugs for treatment of factor IX deficiency Exhibit 19: Special designation to factor IX drugs in 2016 Exhibit 20: A few late-stage (Phase III) factor IX drugs Exhibit 21: Impact of drivers Exhibit 22: Impact of drivers and challenges Exhibit 23: Competitive structure of global factor IX deficiency treatment market 2016 Exhibit 24: Competitive analysis of global factor IX deficiency treatment market Exhibit 25: Market share analysis 2016 Exhibit 26: Market penetration of factor IX vendors 2016 Exhibit 27: Biogen: Key highlights Exhibit 28: Biogen: Strength assessment Exhibit 29: Biogen: Strategy assessment Exhibit 30: Biogen: Opportunity assessment Exhibit 31: Year-over-year (YoY) revenue of ALPROLIX 2014-2016 ($ millions) Exhibit 32: CSL Behring: Key highlights Exhibit 33: CSL Behring: Strength assessment Exhibit 34: CSL Behring: Strategy assessment Exhibit 35: CSL Behring: Opportunity assessment Exhibit 36: Novo Nordisk: Key highlights Exhibit 37: Novo Nordisk: Strength assessment Exhibit 38: Novo Nordisk: Strategy assessment Exhibit 39: Novo Nordisk: Opportunity assessment Exhibit 40: Pfizer: Key highlights Exhibit 41: Pfizer: Strength assessment Exhibit 42: Pfizer: Strategy assessment Exhibit 43: Pfizer: Opportunity assessment Exhibit 44: Shire: Key highlights Exhibit 45: Shire: Strength assessment Exhibit 46: Shire: Strategy assessment Exhibit 47: Shire: Opportunity assessment Exhibit 48: Shire: YoY revenue comparison of RIXUBIS 2014 and 2015 ($ millions)

Biogen, CSL Behring, Novo Nordisk, Pfizer, and Shire.